Medical inflation continues to outpace general CPI, placing increasing pressure on employer-funded healthcare schemes. While some forecasts suggest a moderation in 2026, rising treatment costs, particularly high-cost, unpredictable claims remain the biggest driver of scheme expenditure. For employers, this creates a tension between controlling financial exposure and maintaining the value of benefits for employees.
In this exclusive article, Richard Jones, Data and Pricing Director at Healix Health, explores how stop loss insurance can help employers navigate these challenges, providing financial protection against both unusually large individual claims and cumulative overspend, while preserving the overall integrity of healthcare schemes.
Medical inflation remains a key pressure on employer-funded healthcare schemes, consistently running above the level of CPI. While some market forecasts state an expected reduction in the rate of medical inflation for 2026 compared with 2025, helped further by the ongoing development of claims cost management initiatives by private healthcare providers, it remains the largest single driver of rising costs for these corporate schemes.
For employers funding healthcare benefits, whether through healthcare trusts or private medical insurance schemes, these increases translate directly into greater financial exposure. However, headline inflation figures do not tell the full story.
High-cost claims, with their scale and unpredictability, are often the more pressing concern, particularly as six-figure cases are no longer unusual. When a single claim can significantly affect the overall scheme fund, employers are increasingly reconsidering how much uncertainty they are willing to accept and how best to define the limits of that exposure.
Stop loss becomes a strategic risk tool
That is where stop loss insurance becomes more central to scheme design and is used frequently as part of the healthcare trust solution. Employers could attempt to manage rising costs by reducing benefits or introducing treatment caps, but that directly affects employees and can weaken the overall value of the scheme. Stop loss takes a different approach. It protects the employer’s balance sheet while preserving the level of cover.
There are two main forms of stop loss used in private healthcare schemes. Specific Stop Loss protects against unusually high individual claims. A common structure would see the employer responsible for the first £100,000 of a claim, with the insurer covering costs above that amount. Aggregate Stop Loss protects against total annual claims exceeding a pre-agreed threshold, such as 125% of the agreed claims fund.
Most employers choose to put both protections in place because they address different types of risk. Specific cover limits the financial impact of one unusually large claim. Aggregate cover protects the scheme if overall claims spend exceeds expectations across the year. Together, they create clearer financial boundaries around both individual outlier claims and cumulative overspend.
Protecting benefits without blunt cost-cutting
Once volatility becomes the focus, the conversation naturally turns to the structure of the fund. Reducing cover levels may produce immediate savings, but it can undermine employee confidence in the scheme, which can have wider health and employee retention consequences.
Stop loss allows employers to retain comprehensive benefits while creating financial boundaries. That often involves reviewing where protection attaches. While £100,000 remains the most common specific stop loss threshold, there has been a gradual movement toward £150,000 as employers balance the cost of cover against retained exposure. Among Healix Health clients, aggregate protection typically starts at 115% to 150% of expected claims, reflecting the differing levels of risk appetite from business to business.
Some schemes also build reserves within their trusts by retaining year-on-year surpluses, rather than using them to contribute to scheme costs at renewal. Those reserves can act as a buffer, allowing employers to carry slightly more risk while keeping stop loss premiums proportionate.
What employers should review
Medical inflation increases costs, but it also widens the range of possible outcomes. For a scheme with a £500,000 annual claims fund, a single £250,000 claim can materially affect affordability. Whilst this is particularly pertinent for smaller schemes, even the larger ones will review their existing thresholds and risk appetite in the context of today’s landscape of treatment costs.
Indeed, regular reassessment of both specific and aggregate limits is becoming an important part of scheme governance. Protection levels that were appropriate several years ago may no longer provide the right balance between premium spend and scheme exposure.
In the current environment, stop loss is not simply a precautionary purchase. It is a tool for defining financial boundaries in an increasingly uncertain claims environment. By reviewing protection levels carefully and aligning them with risk appetite, employers can manage volatility in a measured way while maintaining the healthcare benefits their workforce values.
